TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.7430
-0.0127 (-1.68%)
At close: Jul 31, 2026, 4:00 PM EDT
0.7486
+0.0056 (0.75%)
After-hours: Jul 31, 2026, 7:34 PM EDT
TScan Therapeutics Stock Forecast
TCRX's stock price has decreased by -58.95% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 6 analysts polled by S&P Global, TScan Therapeutics stock has a consensus rating of "Buy" and an average price target of $6.00. The average 1-year stock price forecast is 707.54% higher than the current stock price, while the lowest is $5.00 (+572.95%) and the highest is $7.00 (+842.13%).
Price Target: $6.00 (+707.54%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 23, 2026.
Analyst Ratings
The average analyst rating for TScan Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $5 | Buy | Maintains | $5 | +572.95% | Jun 23, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 23, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $6 | Buy | Maintains | $6 | +707.54% | Jun 23, 2026 |
| Needham | Needham | Buy Reiterates $6 | Buy | Reiterates | $6 | +707.54% | Jun 23, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $7 | Buy | Reiterates | $7 | +842.13% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
7.56M
from 10.33M
Decreased by -26.80%
Revenue Next Year
7.81M
from 7.56M
Increased by 3.30%
EPS This Year
-0.84
from -1.00
EPS Next Year
-0.89
from -0.84
EPS and Forward PE are based on non-GAAP adjusted numbers.